Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D
Cancer focused and charging forwards, AbbVie makes 2017 the year its pipeline will expand a little more. Scrip looks at the company’s growing oncology portfolio and what is yet to come and speaks to medical affairs head Bianca Wittig about challenges intertwined with oncology R&D.
You may also be interested in...
CEO says the idea of forming one company around Humira and its earnings and another around the R&D pipeline holds merit but he wants to wait to see the outcome of US tax reform, which could address some of AbbVie's issues.
New data position BCL-2 inhibitor Venclexta, partnered with Roche, for roles in multiple myeloma and acute myeloid leukemia, among other indications beyond chronic lymphocytic leukemia.
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.